Drug intelligence / Profile preview

QS-21 (Aquila Biopharmaceuticals)

Development stage
Unknown
Lead developer
Agenus
Modality
Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Subcutaneous
01

Overview

QS-21 is a purified **Quillaja saponaria** triterpene-saponin fraction used as an immunostimulatory vaccine adjuvant. In the University of Virginia Phase 1 melanoma study NCT00003224, QS-21 was administered subcutaneously as an adjuvant with peptide 946-based melanoma vaccine constructs, with or without tetanus helper peptide; it was not itself the melanoma antigen vaccine. QS-21 is intended to amplify antigen-specific cellular and humoral immune responses rather than directly target melanoma cells. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00003224))

Brand names
Stimulon
Other names
QS21QS-21QS 21Saponin QS-21
02

Targets

PMEL (Melanocyte Protein PMEL)

Beyond the preview

Go deeper on QS-21 (Aquila Biopharmaceuticals).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on QS-21 (Aquila Biopharmaceuticals).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call